RICHLAND, Wash., June 21, 2022 (GLOBE NEWSWIRE) -- The growing body of information regarding Isoray, Inc.’s (NYSEAmerican:ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference in Denver, Colorado.
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here